BioCentury: The Bernstein Report on BioBusiness recently featured ApopLogic Pharmaceuticals in their weekly publication. As a trusted global leader in the distribution of biobusiness intelligence it makes me feel all warm inside that the publication is sourcing stories in our own backyard.
ApopLogic is a pre-clinical company focused on apoptosis-inducing compounds. Six patents have been issued covering the use of bradykinin antagonists and Fas ligand. Lead products are Breceptin (a novel neuropeptide growth factor receptor antagonist targeting a broad range of cancers), Cytonil (a combination of cell-type specific growth factor and a cell signaling agonist to treat Sezary leukemia, cutaneous T cell lymphoma and psoriasis), and Fasaret (an apoptotic cell death-inducing molecule with unique pro- inflammatory properties for the treatment of cancers).